newsRezlidhia™ has been approved for adults with mIDH1 relapsed/refractory acute…
2 December 2022 | By Catherine Eckford (European Pharmaceutical Review)
Rezlidhia™ has been approved for adults with mIDH1 relapsed/refractory acute myeloid leukaemia by the US Food and Drug Administration (FDA).